Utilización de la nanotecnología en la prevención de la diabetes mellitus tipo 1: modificando genes para salvar vidas
Palabras clave:
Diabetes mellitus tipo 1, nanotecnología, modificación génica, tratamiento antidiabéticoResumen
La diabetes mellitus tipo 1 (DM1) es una condición médica con una alta tasa de morbilidad y mortalidad para la cual aún no existe una cura. Aunque el correcto manejo médico con terapia insulínica mejora la calidad de vida de los pacientes y disminuye la aparición de complicaciones, la problemática persiste. Por ende, urge la necesidad de buscar soluciones alternativas. La modificación del sistema inmunológico por inducción de tolerancia o por modificación genética ha ganado popularidad en los últimos años, sobre todo con los recientes avances en nanotecnología. El objetivo de esta revisión es evaluar la evidencia actual en relación a las intervenciones con nanotecnología y modificación génica en el contexto de pacientes con DM1, con la intención de evaluar su efectividad y viabilidad en el ámbito clínico.
Descargas
Citas
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020 Dec 4;44(Supplement_1):S15–33.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–11.
Atkinson MA. The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harb Perspect Med. 2012 Nov;2(11):a007641.
Menke A, Orchard TJ, Imperatore G, Bullard KM, Mayer-Davis E, Cowie CC. The prevalence of type 1 diabetes in the United States. Epidemiol Camb Mass. 2013 Sep;24(5):773–4.
Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method. PLOS ONE. 2010 Jul 9;5(7):e11501.
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet Lond Engl. 2018 Jun 16;391(10138):2449–62.
Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643–53.
Pan W, Zheng X, Chen G, Su L, Luo S, Wang W, et al. Nanotechnology’s application in Type 1 diabetes. WIREs Nanomedicine Nanobiotechnology [Internet]. 2020 Nov [cited 2022 May 2];12(6). Available from: https://onlinelibrary.wiley.com/doi/10.1002/wnan.1645
Gong R, Chen G. Preparation and application of functionalized nano drug carriers. Saudi Pharm J. 2016 May 1;24(3):254–7.
Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007 Dec;2(4):MR17-71.
Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006 Dec 1;58(14):1456–9.
Lombardo D, Kiselev MA, Caccamo MT. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J Nanomater. 2019 Feb 27;2019:e3702518.
Husseini GA, Pitt WG. Micelles and Nanoparticles for Ultrasonic Drug and Gene Delivery. Adv Drug Deliv Rev. 2008 Jun 30;60(10):1137–52.
Aziz Z, Mohd Nasir H, Ahmad A, Mohd-Setapar S, Peng W, Chuo SC, et al. Role of Nanotechnology for Design and Development of Cosmeceutical: Application in Makeup and Skin Care. Front Chem. 2019 Nov 13;7.
Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep. 2021 May;14(5):42.
Cash KJ, Clark HA. Nanosensors and nanomaterials for monitoring glucose in diabetes. Trends Mol Med. 2010 Sep 23;16(12):584–93.
Bahman F, Greish K, Taurin S. Nanotechnology in Insulin Delivery for Management of Diabetes. Pharm Nanotechnol. 2019;7(2):113–28.
Nigam S, Bishop JO, Hayat H, Quadri T, Hayat H, Wang P. Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances. Pharmaceutics. 2022 Mar;14(3):644.
Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2017 Nov 30;7(1):R38–46.
Desai S, Buchade S, Chitlange S, Sharma H, Bhombe D, Shewale S, et al. Vaccines For Type 1 Diabetes: Prevention or Reversal? Curr Diabetes Rev. 2021;17(1):30–6.
Serra P, Garabatos N, Singha S, Fandos C, Garnica J, Solé P, et al. Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules. Nat Commun. 2019 Oct 29;10(1):4917.
Yoon YM, Lewis JS, Carstens MR, Campbell-Thompson M, Wasserfall CH, Atkinson MA, et al. A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep. 2015 Aug 17;5(1):13155.
Lewis JS, Dolgova NV, Zhang Y, Xia CQ, Wasserfall CH, Atkinson MA, et al. A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice. Clin Immunol. 2015 Sep 1;160(1):90–102.
Chen N, Kroger CJ, Tisch RM, Bachelder EM, Ainslie KM. Prevention of Type 1 Diabetes with Acetalated Dextran Microparticles Containing Rapamycin and Pancreatic Peptide P31. Adv Healthc Mater. 2018 Sep;7(18):1800341.
Yeste A, Takenaka MC, Mascanfroni ID, Nadeau M, Kenison JE, Patel B, et al. Tolerogenic nanoparticles inhibit T cell–mediated autoimmunity through SOCS2. Sci Signal. 2016 Jun 21;9(433):ra61–ra61.
Chellappan DK, Sivam NS, Teoh KX, Leong WP, Fui TZ, Chooi K, et al. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother. 2018 Dec 1;108:1188–200.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017 Sep;12(9):877–82.
Lee M, Ko KS, Oh S, Kim SW. Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10. J Controlled Release. 2003 Mar 7;88(2):333–42.
Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. A Microsphere-Based Vaccine Prevents and Reverses New-Onset Autoimmune Diabetes. Diabetes. 2008 Jun 1;57(6):1544–55.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Diabetes Internacional y Endocrinologia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
